Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893816 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL9943129 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL25982822 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL14393664 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL25353980 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL16330602 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL12462467 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL10271866 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL14543511 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL14707099 | 0.83 | SMN1; SMN2 (0.39) | SMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | SMN1; SMN2 3503/4885GNAI3 2674/4885GNAO1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.